Cranial cruciate ligament (CCL) rupture is one of the most common orthopedic disorders in dogs and is associated with pain, joint instability, lameness, and progressive osteoarthritis. Although surgical stabilization is widely used, conservative management remains relevant in selected cases, particularly in smaller dogs or when surgery is declined or contraindicated.
Radio Electric Asymmetric Conveyer (REAC) technology is a non-invasive therapeutic platform designed to modulate endogenous bioelectrical activity, with a proposed role in neuromotor regulation and tissue repair. This study was designed as a translational, hypothesis-generating pilot investigation to assess whether a standardized REAC-based treatment protocol could produce a coherent and durable clinical signal in dogs with naturally occurring CCL rupture. Sixteen client-owned dogs with mono- or bilateral CCL rupture were enrolled and stratified by body weight into two groups: ≤15 kg and > 15 kg. All dogs received a standardized protocol including Veterinary Neuro Postural Optimization (VNPO), Veterinary Neuro Psycho Physical Optimization (VNPPO), and Reparative Tissue Optimization (TO-RPR).
Clinical outcomes were assessed by standardized orthopedic examination at baseline, within 15 days after treatment completion, and at 2- and 12-month follow-up. All dogs completed treatment and follow-up. In dogs weighing ≤ 15 kg, complete functional recovery was observed in all cases. In dogs weighing > 15 kg, most showed either complete recovery or clinically meaningful improvement, while one dog was classified as a non-responder and referred for surgical evaluation. Clinical improvements observed in responder dogs remained stable at 12 months.
These findings do not constitute definitive evidence of efficacy, but suggest the presence of a coherent and durable clinical signal supporting further investigation of REAC-based treatment as a conservative or adjunctive strategy in canine CCL disease. Future controlled studies incorporating objective biomechanical, imaging, and biological outcome measures are warranted.
